Invest now
Kopran share price
High risk
You have to be logged in to add this to Watchlist.- ₹260.90(-0.31%)October 13, 2026 15:29:33 PM IST
- NSE
- BSE
- Vol : 509.78 K (NSE + BSE)Last 20 day avg : 2.38 M
Kopran is trading -0.31% lower at Rs 260.90 as compared to its last closing price. Kopran has been trading in the price range of 266.45 & 246.05. Kopran has given 73.84% in this year & -2.68% in the last 5 days. Kopran has TTM P/E ratio 36.41 as compared to the sector P/E of 34.46.The company posted a net profit of 6.70 Crores in its last quarter.Listed peers of Kopran include Sun Pharmaceutical Industries (0.57%), Divi's Laboratories (-1.11%), Torrent Pharmaceuticals (-0.94%).The Mutual Fund holding in Kopran was at 0.94% in 31 Mar 2024. The MF holding has increased from the last quarter. The FII holding in Kopran was at 0.91% in 30 Sep 2026. The FII holding has increased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Loading...
Key Metrics
Updated on 13 Oct 2026, 07:35 PM IST
- BetaHigh volatility1.21Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.29The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldHigher than industry1.19Annual dividends as a percentage of the stock price.
- P/BHigher than historical values2.29The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values48.28Price-to-earnings ratio based on trailing 12-month earnings
- PEG RatioIndicates undervaluation-25.57The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Kopran Peers
Return Comparison
Peers Comparison
Names | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 1,769.10 | 0.57 | 4,24,456.35 | 38.40 | 5.55 | 0.83 | 0.47 |
| Divi's Laboratories | 9,275.00 | -1.11 | 2,46,222.10 | 73.32 | 11.48 | 0.41 | 0.03 |
| Torrent Pharmaceuticals | 4,635.00 | -0.94 | 1,76,294.19 | 72.73 | 19.22 | 0.80 | 141.16 |
| Cipla | 1,330.00 | 1.24 | 1,07,445.17 | 27.57 | 3.33 | 0.92 | 1.11 |
| Zydus Lifesciences | 1,131.00 | -0.70 | 1,12,817.68 | 21.19 | 4.24 | 0.09 | 14.22 |
Mutual Fund Ownership
View allKopran Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-08-07 | Quarterly Results |
| 2026-05-19 | Audited Results & Final Dividend |
| 2026-01-22 | Quarterly Results |
| 2025-11-12 | Quarterly Results |
| 2025-07-29 | Quarterly Results |
About the company Kopran
- IndustryBiotechnology & Drugs
- ISININE082A01010
- BSE Code524280
- NSE CodeKOPRAN
Kopran Limited is an India-based pharmaceutical company. The Company is primarily engaged in the business of manufacturing of formulation (finished dosage form) and active pharmaceutical ingredients (API). Its formulations product categories include penicillin-based finished oral dosage forms and non-penicillin-based finished oral dosage forms. The Company's penicillin-based finished oral dosage forms include amoxycillin, ampicillin, cloxacillin, amoxy clauv, flucloxacillin, and phenoxy methyl penicillin. Its non-penicillin-based finished oral dosage forms include macrolides, cardiovascular, anti-helmentics, antihistamine, anti-diabetic, pain management, gastroenterology, and respiratory. It has a portfolio, producing over 100 dosage forms. These include tablets, capsules, dry powder, suspension and injectables. Its subsidiary, Kopran Research Laboratories Ltd, manufactures a range of APIs, including Atenolol and Sterile Carbapenems.
Kopran Share Price FAQs
Kopran is trading at 260.90 as on Tue Oct 13 2026 09:59:33. This is -0.31% lower as compared to its previous closing price of 261.70.
The market capitalization of Kopran is 1255.55 Cr as on Tue Oct 13 2026 09:59:33.
The 52 wk high for Kopran is 295.90 whereas the 52 wk low is 107.00
Kopran can be analyzed on the following key metrics -
- TTM P/E: 36.41
- Sector P/E: 34.46
- Dividend Yield: 1.15%
- D/E ratio: -
Kopran reported a net profit of 25.73 Cr in 2026.
The Mutual Fund Shareholding was 0.94% at the end of 31 Mar 2024.
Quick Links
EQUITY QUICK LINKS
Kopran QUICK LINKS
FROM MARKETS
RELATED LINKS
Quarterly Results
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.